Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)

This trial is studying how the biology and immune activity of prostate cancer with only a few metastases (oligometastatic prostate cancer) can guide treatment decisions, by analyzing tumor DNA in the blood and cancer cells. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with hormone-sensitive prostate cancer that has spread to 3 or fewer metastases in the bone and/or lymph nodes, detected in the past 6 months by a PSMA or choline PET-CT scan after a rising PSA following prostate treatment - Biopsy confirmation of prostate cancer is required **You may NOT be eligible if...** - Your cancer has spread to more than 3 sites - Your cancer is no longer responding to hormone treatment (castration-resistant) - You have had prior chemotherapy for metastatic prostate cancer Talk to your doctor to see if this trial is right for you.